HK1179623A1 - Inhibitors of protein kinases - Google Patents
Inhibitors of protein kinasesInfo
- Publication number
- HK1179623A1 HK1179623A1 HK13106821.7A HK13106821A HK1179623A1 HK 1179623 A1 HK1179623 A1 HK 1179623A1 HK 13106821 A HK13106821 A HK 13106821A HK 1179623 A1 HK1179623 A1 HK 1179623A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- protein kinases
- kinases
- protein
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33986610P | 2010-03-10 | 2010-03-10 | |
PCT/EP2011/053574 WO2011110612A1 (en) | 2010-03-10 | 2011-03-10 | Inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1179623A1 true HK1179623A1 (en) | 2013-10-04 |
Family
ID=43809024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13106821.7A HK1179623A1 (en) | 2010-03-10 | 2013-06-09 | Inhibitors of protein kinases |
Country Status (15)
Country | Link |
---|---|
US (3) | US8518948B2 (xx) |
EP (1) | EP2545037A1 (xx) |
JP (1) | JP2013521324A (xx) |
KR (1) | KR20130016244A (xx) |
CN (1) | CN102834380B (xx) |
AU (1) | AU2011226073B2 (xx) |
BR (1) | BR112012022511A2 (xx) |
CA (1) | CA2789189A1 (xx) |
EA (1) | EA201201274A1 (xx) |
HK (1) | HK1179623A1 (xx) |
IL (1) | IL221311A (xx) |
MX (1) | MX2012010471A (xx) |
NZ (2) | NZ601924A (xx) |
SG (1) | SG183192A1 (xx) |
WO (1) | WO2011110612A1 (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
BR112015009850A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase |
US9546153B2 (en) | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
CA2891013A1 (en) | 2012-11-16 | 2014-05-22 | Abdelghani Abe Achab | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
WO2014160729A1 (en) * | 2013-03-28 | 2014-10-02 | Cellworks Research India Pvt. Ltd | Composition and method for treating cancer |
TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎cyp17抑制劑/抗雄激素劑 |
PL3057959T3 (pl) * | 2013-10-17 | 2018-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitory DNA-PK |
CN104437130B (zh) * | 2014-11-06 | 2016-08-31 | 沈鹏 | 一种可降解型中空纤维膜及其制备方法 |
US9845331B2 (en) | 2015-06-29 | 2017-12-19 | Astrazeneca Ab | Chemical compounds |
AU2018380132B2 (en) * | 2017-12-06 | 2023-11-09 | Lin Bioscience, Inc. | Tubulin inhibitors |
CN114728179A (zh) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | 利用pd-1激动剂的靶向免疫耐受 |
AU2020378009A1 (en) * | 2019-11-05 | 2022-05-26 | Dermira, Inc. | MrgprX2 antagonists and uses thereof |
KR20220113773A (ko) * | 2019-12-09 | 2022-08-16 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 사이클린 의존성 키나아제 9 억제제로서의 화합물 및 그의 용도 |
EP4141004A4 (en) * | 2020-05-12 | 2023-08-23 | Suzhou Alphama Biotechnology Co., Ltd. | POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE |
JP7451765B2 (ja) * | 2020-05-12 | 2024-03-18 | 蘇州阿尓脈生物科技有限公司 | Cdk阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途 |
JP2024502083A (ja) * | 2020-12-31 | 2024-01-17 | 清華大学 | ピリジン-2-アミン誘導体、その医薬組成物、及び使用 |
WO2022257965A1 (zh) * | 2021-06-09 | 2022-12-15 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
WO2024009232A1 (en) * | 2022-07-05 | 2024-01-11 | Aurigene Oncology Limited | Substituted n-(pyridin-2-yl)acetamide derivatives as cdk12/13 inhibitors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0784462B2 (ja) | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
HUP0300029A2 (en) | 2000-02-25 | 2003-05-28 | Hoffmann La Roche | Adenosine receptor modulators, pharmaceutical compositions containing them and their use |
US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
MXPA03008888A (es) * | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
AR036053A1 (es) * | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
WO2004084824A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
SE0301963D0 (sv) * | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
AU2004261484A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
EP1648887A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
BRPI0510095A (pt) | 2004-04-20 | 2007-10-16 | Transtech Pharma Inc | tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina |
FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
EP2027087A2 (en) * | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
US7544306B2 (en) * | 2007-02-16 | 2009-06-09 | Honeywell International Inc. | Azeotropic fumigant compositions of methyl iodide |
ATE510827T1 (de) * | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
US20110230497A1 (en) | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
UA103918C2 (xx) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(гетеро)арил, 2-(гетеро)арилзаміщені ацетаміди для застосування як модуляторів wnt передачі сигналу$n-(гетеро)арил, 2-(гетеро)арилзамещенные ацетамиды для применения как модуляторов wnt передачи сигнала |
CA2771568A1 (en) * | 2009-09-04 | 2011-03-10 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
-
2011
- 2011-03-10 JP JP2012556514A patent/JP2013521324A/ja not_active Ceased
- 2011-03-10 WO PCT/EP2011/053574 patent/WO2011110612A1/en active Application Filing
- 2011-03-10 NZ NZ601924A patent/NZ601924A/en not_active IP Right Cessation
- 2011-03-10 EP EP11708026A patent/EP2545037A1/en not_active Withdrawn
- 2011-03-10 BR BR112012022511A patent/BR112012022511A2/pt not_active IP Right Cessation
- 2011-03-10 AU AU2011226073A patent/AU2011226073B2/en not_active Ceased
- 2011-03-10 CN CN201180012835.3A patent/CN102834380B/zh not_active Expired - Fee Related
- 2011-03-10 SG SG2012058145A patent/SG183192A1/en unknown
- 2011-03-10 MX MX2012010471A patent/MX2012010471A/es active IP Right Grant
- 2011-03-10 EA EA201201274A patent/EA201201274A1/ru unknown
- 2011-03-10 KR KR1020127025774A patent/KR20130016244A/ko not_active Application Discontinuation
- 2011-03-10 US US12/932,955 patent/US8518948B2/en not_active Expired - Fee Related
- 2011-03-10 NZ NZ627520A patent/NZ627520A/en not_active IP Right Cessation
- 2011-03-10 CA CA2789189A patent/CA2789189A1/en not_active Abandoned
-
2012
- 2012-08-05 IL IL221311A patent/IL221311A/en not_active IP Right Cessation
-
2013
- 2013-06-09 HK HK13106821.7A patent/HK1179623A1/xx not_active IP Right Cessation
- 2013-08-27 US US14/011,057 patent/US9067888B2/en not_active Expired - Fee Related
-
2015
- 2015-06-11 US US14/736,589 patent/US20150272947A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013521324A (ja) | 2013-06-10 |
KR20130016244A (ko) | 2013-02-14 |
US20130345233A1 (en) | 2013-12-26 |
NZ601924A (en) | 2014-10-31 |
US8518948B2 (en) | 2013-08-27 |
US9067888B2 (en) | 2015-06-30 |
CN102834380B (zh) | 2015-04-01 |
AU2011226073B2 (en) | 2015-05-28 |
US20150272947A1 (en) | 2015-10-01 |
MX2012010471A (es) | 2012-10-09 |
CN102834380A (zh) | 2012-12-19 |
BR112012022511A2 (pt) | 2016-08-30 |
NZ627520A (en) | 2015-10-30 |
EA201201274A1 (ru) | 2013-04-30 |
EP2545037A1 (en) | 2013-01-16 |
IL221311A (en) | 2015-08-31 |
CA2789189A1 (en) | 2011-09-15 |
IL221311A0 (en) | 2012-10-31 |
AU2011226073A1 (en) | 2012-09-27 |
SG183192A1 (en) | 2012-09-27 |
WO2011110612A1 (en) | 2011-09-15 |
US20110224225A1 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254345B (zh) | Cdk抑制劑 | |
HK1179623A1 (en) | Inhibitors of protein kinases | |
HK1167142A1 (en) | Imidazopyrazines as inhibitors of protein kinases | |
IL208719A0 (en) | Inhibitors of protein kinases | |
HK1200451A1 (zh) | 蛋白激酶抑制劑 | |
HK1202333A1 (en) | Combination of kinase inhibitors and uses thereof | |
HK1215578A1 (zh) | 作為蛋白激酶抑制劑的氮雜吲哚衍生物 | |
HK1202529A1 (zh) | 非典型性蛋白激酶 的噻吩並嘧啶類抑制劑 | |
EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
EP2590982A4 (en) | PROTEIN INHIBITOR KINASES AND METHODS OF TREATMENT | |
ZA201206456B (en) | Uses of dgati inhibitors | |
ZA201306855B (en) | Protein kinase inhibitors | |
IL225605A0 (en) | Polo-like kinase inhibitors | |
HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
ZA201207482B (en) | Inhibitors of protein tyrosine kinase activity | |
HK1182383A1 (zh) | 激酶抑制劑的結晶形式 | |
EP2714667A4 (en) | AMINOOXAZOLE INHIBITORS OF KINASES DEPENDENT OF CYCLIN | |
EP2665727A4 (en) | KINASE INHIBITORS BASED ON BICYCLIC CARBOXAMIDES | |
GB0907120D0 (en) | Inhibitors of IKK-ß serine-threonine protein kinase | |
HK1182384A1 (en) | Crystalline forms of kinase inhibitors | |
HK1179255A1 (en) | Crystalline forms of kinase inhibitors | |
GB201003949D0 (en) | Inhibitors of protein kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190308 |